Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Medical Care Reports Strong Third Quarter and

Nine Months 2007 Results; Outlook

Now Confirmed at Upper End

Bad Homburg, Germany Fresenius Medical Care AG & Co. KGaA

( the Company ), the world s largest provider of Dialysis Products and

Services, today announced its results for the third quarter and nine months of

Net revenue for the third quarter 2007 increased by 9%

to $2,426 million (6% at constant currency) compared to the third quarter 2006.

Organic revenue growth worldwide was 6%. Dialysis Services revenue grew by 6%

to $1,801 million (4% at constant currency) in the third quarter of 2007.

Dialysis Product revenue increased by 18% to $625 million (12% at constant

currency) in the same period.

North America revenue increased by 3% to $1,660 million.

Dialysis Services revenue grew by 1% to $1,494 million. Excluding effects of

the divestiture of the perfusion business, Dialysis Service revenue increased

by 3%. Average revenue per treatment for the U.S. clinics increased by 1% to

$327 in the third quarter 2007 compared to $324 for the same quarter in 2006.

Dialysis Product revenue increased by 18% to $167 million led by strong sales

of our 2008K hemodialysis machines and the phosphate binding drug PhosLo.

International revenue was $766 million, an increase of 23%

(14% at constant currency) compared to the third quarter of 2006. Dialysis

Services revenue reached $307 million, an increase of 32% (23% at constant

currency). Dialysis Product revenue rose by 18% to $459 million (9% at constant

currency), led by strong sales of hemodialysis machines, peritoneal dialysis

products and dialyzers.

by 14% to $397 million compared to $349 million in the third quarter 2006.

Operating income for the third quarter 2006 includes costs of $7 million

related to costs of restructuring and a gain of $1 million from the divestiture

of dialysis clinics in conjunction with the acquisition of Renal Care Group. Excluding

these effects, operating income for the third quarter 2007 increased by 12%,

resulting in an operating margin of 16.4%. For the third quarter 2006 the

operating margin was 15.9%.

In North America, the operating margin increased from 16.3% (excluding

the effects of one-time items) by 70 basis points to 17.0% due to revenue rate

improvements, the new PhosLo business and higher product sales which more than

offset higher personnel expenses. In the International segment, the operating

margin decreased by 60 basis points to 17.6% mainly due to higher growth in the

emerging markets and the effect of returning to normal plant maintenance from

the shortened schedule in the prior year.

Net interest expense for the third quarter 2007 was $95 million

compared to $100 million in the same quarter of 2006. This positive development

was mainly attributable to a lower debt level in combination with lower average

interest rates and the recognition of interest income related to the collection

of overdue receivables. Interest expense was impacted by $5 million ($3

million, net after taxes) as a result of the write-off of deferred financing

costs related to the repayment of a portion of the Company s senior credit

agreement in connection with the issuance of $500 million senior notes.

Income tax expense was $115 million for the third quarter of

2007 compared to $105 million in the third quarter of 2006, reflecting

effective tax rates of 38.0% and

42.3%, respectively. In the third quarter 2006, the tax rate had been impacted

by a tax audit in Germany. Excluding this impact, the tax rate was at 39.1%.

Net income for the third quarter 2007 was $181

million, an increase of 30%. Net income increased by 27% when compared to the

third quarter 2006 excluding the effects of one-time items in 2006.

(EPS) for the third quarter

of 2007 rose by 29% to $0.61 per ordinary share compared to $0.47 for the third

quarter of 2006. The weighted average number of shares outstanding for the

third quarter of 2007 was approximately 295.8 million shares compared to 294.5

million shares for the third quarter of 2006. The increase in shares

outstanding resulted from stock option exercises in 2006 and in the first nine

In the third quarter of 2007, the Company generated $382 million in cash from operations, representing

approximately 16% of revenue. The strong cash flow generation was primarily

supported by earnings and reduction of working capital.

A total of $123 million was spent for capital

expenditures, net of disposals. Free

Cash Flow before acquisitions was $259 million compared to $40

million in the third quarter of 2006 on a reported basis. A total of $24

million in cash was used for acquisitions,

net of divestitures. Free Cash Flow after

acquisitions was $235 million compared to $32 million in the third

Nine Months Ended September 30,

Renal Care Group (RCG) are included in the Company s consolidated statements of

income and cash flows from April 1, 2006, therefore, the current results for

the first nine months are not directly comparable with the results of the first

nine months for 2006.

Revenue and Earnings

Net revenue for the nine months ended September 30,

2007 was $7,151 million, up 16% from the same period in 2006. At constant

currency, net revenue rose by 14%. Organic growth was 7% in the first nine

increased by 19% to $1,152 million compared to $964 million in the first nine

months of 2006. Operating income for the nine months ended September 30, 2006

includes costs of $12 million as a result of restructuring and the

transformation of the Company s legal form, and a gain from the clinic

divestitures of $40 million.

Excluding these items, operating income for the nine months 2007 increased

by 23%. This performance resulted in an operating margin of 16.1% compared to

15.2% in the same period of 2006.

Net interest expense for the nine months ended September 30,

2007 was $281 million compared to $255 million in the same period of 2006. The

increase was mainly the result of additional interest expense partially offset

by the write-off in 2006 of deferred financing costs related to the 2003 senior

credit facility of $15 million, both in conjunction with the financing of the

Income tax expense was $331 million for the nine months

compared to $314 million in the same period in 2006, reflecting tax rates of 38.0% and 44.3%, respectively.